Schrodinger expects ACV to increase 12 to 17% this year off of 198; Bunsen remains in beta and the company is seeing license growth. The hosted transition targets 75% hosted by 2028.
SDGR · Schrodinger, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 36%
- Last earnings
- Nov 4, 2026
- Latest filing
- 10-Q · Nov 4
- Price history
- Feb 2020 to Nov 2026
Up next
Latest documents
Schrodinger raised full-year 2026 ACV guidance to $222 to $232 million and drug discovery revenue guidance to $75 to $85 million after 17% third-quarter ACV growth.
Schrodinger generated revenue of $64.5 million for the three months ended September 30, 2026, up 19% from $54.3 million, while net loss widened to $37.7 million from $32.8 million.
Schrödinger reported third-quarter ACV of $44.7 million, up 17%, and raised 2026 ACV guidance to $222 million to $232 million and drug discovery revenue guidance to $75 million to $85 million. It clarified that no SGR-1505 combination study had been initiated under its FDA-cleared protocol.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q3 FY26 earnings call · Nov 4, 2026TL;DR. Schrodinger delivered 17% ACV growth, 19% total revenue growth and 49% hosted software revenue growth, raised full-year ACV and drug discovery revenue guidance, reduced operating expenses and ended the quarter with $373 million of cash, cash equivalents, restricted cash and marketable securities. Platform initiatives and the therapeutics portfolio advanced, while the main negatives were a wider net loss and equity-investment mark-to-market expense, lower software gross margin, operating cash outflow, temporary hosted-transition revenue pressure, limited milestone visibility and the lack of an initiated SGR-1505 combination study.
- + Full-year drug discovery revenue guidance was raised to $75 million–$85 million from $65 million–$75 million. new
- − Software gross margin declined to 75% from 77% due to the transition to hosted software licensing.
- − The hosted-license transition temporarily reduces reported software revenue. new
- − Future milestone timing has limited visibility despite the company's milestone track record. new
- − An SGR-1505 combination study had not been initiated, and the company is exploring strategic opportunities to continue development. new
- − Nine-month net cash used in operating activities was (96,482) thousand, compared with 29,992 thousand provided in the prior-year period. new
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| ACV | $44.7M | third quarter 2026 | — |
| Adjusted EBITDA non-GAAP | -$85.47M | Nine Months Ended September 30, 2026 | — |
| Cash, cash equivalents, restricted cash and marketable securities | $373M | September 30, 2026 | — |
| Hosted software revenue as percent of total software revenue | 32% | trailing four-quarter basis | — |
| Annual contract value (ACV) non-GAAP | $29.6M | the three months ended June 30, 2026 filing | — |
| Software gross margin | 71% | Q2 2026 | — |
| Software products and services gross margin | 71% | the three months ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Health Information Services — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SDGR
this stock
Schrodinger, Inc.
|
$1.72B | +28.2% | +23.3% | — | 13.0% |
|
VEEV
Veeva Systems Inc
|
$43.10B | +19.3% | +28.1% | 43.6 | 2.4% |
|
PMDIY
Pro Medicus Ltd.
|
$14.81B | -14.6% | — | — | 0.0% |
|
BTSG
BrightSpring Health Services, Inc.
|
$12.50B | +67.8% | +28.2% | 34.2 | 5.8% |
|
TEM
Tempus AI, Inc.
|
$9.86B | -8.5% | +83.4% | — | 13.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 10, 2026
- This year
- 20
Schrodinger expects ACV to increase 12 to 17% this year off of 198; Bunsen remains in beta and the company is seeing license growth. The hosted transition targets 75% hosted by 2028.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SDGR | -22.4% | -3.7% | +53.5% | -15.5% | +28.2% |
| SPY | -8.6% | -9.2% | -9.2% | -8.7% | +1.2% |
| vs SPY | -13.8% | +5.6% | +62.7% | -6.8% | +27.1% |